Last reviewed · How we verify

OBE001 — Competitive Intelligence Brief

OBE001 (OBE001) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxytocin receptor antagonist; Tocolytic agent. Area: Other.

discontinued Oxytocin receptor antagonist; Tocolytic agent Oxytocin receptor (OXTR) Other Small molecule Live · refreshed every 30 min

Target snapshot

OBE001 (OBE001) — ObsEva SA. OBE001 is an oxytocin receptor antagonist that inhibits uterine contractions by blocking oxytocin signaling in myometrial smooth muscle.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OBE001 TARGET OBE001 ObsEva SA discontinued Oxytocin receptor antagonist; Tocolytic agent Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxytocin receptor antagonist; Tocolytic agent class)

  1. ObsEva SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OBE001 — Competitive Intelligence Brief. https://druglandscape.com/ci/obe001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: